Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=310 Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
Hepatitis B · Polio · Diphtheria
Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…
N/A N=26 A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD
Combat Disorders · Stress Disorders, Post-Traumatic
Primary: Clinician Administered PTSD Scale-IV — 69.85; 73.38 units on a scale
Early Phase 1 N=41 Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates
Ventilator-associated Pneumonia
Primary: Feasibility — 100; 100 percentage of participants retained
N/A N=1,359 An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)
Cancer
Primary: Crude Rate of Newly Diagnosed Cancer-Follow-up Primary Cohort — 1.14; 2.07 per 100 participant-years
Phase 3 N=49 A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 95.9 Percentage of participants
Phase 2 N=90 AGN-229666 for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
N/A N=39 Multifocal Lens Design Evaluation
Refractive Error · Presbyopia
Primary: Mean Binocular HC/HI Visual Acuity at Near (40 cm) — 0.08; 0.06; 0.05; 0.05 logMAR
Phase 2 N=21 Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)
Peripheral Artery Disease
Primary: Incidence of Major Adverse Events (MAEs) — 0; 0 participants
Phase 3 N=3 Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
Severe Hemophilia A
Primary: Long-term Immunogenicity — 0 occurrence of inhibitors
Phase 2 N=74 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Leukemia
Primary: Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) — 1; 2; 0; 2 participants
Phase 2 N=61 An Exploratory Study of Nesiritide in Participants With Acute Heart Failure
Heart Failure, Congestive
Primary: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP or Pulmonary Arterial Diastolic Pressure[PADP]) at 3 Hours — 27.7; 24.8; 29.7; -6.7 Millimeters of…
N/A N=44 Study of ACUVUE® ADVANCE® PLUS Contact Lenses.
Myopia
Primary: Visual Acuity (VA) — -0.088; -0.083 logMAR scale
N/A N=36 Pilot Dispensing Evaluation of a Plus Power Lens
Hyperopia
Primary: Visual Acuity One Week After Lens Wear — 0.11; 0.10; 0.14; 0.14 LogMAR
N/A N=20 Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)
Axillary Hyperhidrosis
Primary: Percentage Change of Sweat Rate (mg/Min) at Baseline Compared to 3 Months — 73.8; 58.8 Percentage Change — p=>0.01